Docoh
Loading...

STAA Staar Surgical

Filed: 5 Aug 20, 4:12pm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended:    July 3, 2020

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 0-11634

 

STAAR SURGICAL COMPANY

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

95-3797439

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

25651 Atlantic Ocean Drive
Lake Forest, California

 

92630

(Address of Principal Executive Offices)

(Zip Code)

 

(626) 303-7902

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

STAA

NASDAQ

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes      No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes      No 

The registrant has 45,806,406 shares of common stock, par value $0.01 per share, issued and outstanding as of July 31, 2020.

 


STAAR SURGICAL COMPANY

 

INDEX

 

 

 

 


PART I – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amounts)

(Unaudited)

 

 

 

July 3, 2020

 

 

January 3, 2020

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

116,315

 

 

$

119,968

 

Accounts receivable trade, net of allowance of doubtful accounts of

   $52 and $88, respectively

 

 

39,469

 

 

 

30,996

 

Inventories, net

 

 

17,836

 

 

 

17,142

 

Prepayments, deposits and other current assets

 

 

8,897

 

 

 

6,560

 

Total current assets

 

 

182,517

 

 

 

174,666

 

Property, plant and equipment, net

 

 

21,478

 

 

 

17,065

 

Finance lease right-of-use assets, net

 

 

687

 

 

 

1,867

 

Operating lease right-of-use assets, net

 

 

5,587

 

 

 

6,684

 

Intangible assets, net

 

 

280

 

 

 

296

 

Goodwill

 

 

1,785

 

 

 

1,786

 

Deferred income taxes

 

 

5,114

 

 

 

3,750

 

Other assets

 

 

591

 

 

 

751

 

Total assets

 

$

218,039

 

 

$

206,865

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Line of credit

 

$

1,325

 

 

$

1,827

 

Accounts payable

 

 

8,890

 

 

 

8,050

 

Obligations under finance leases

 

 

493

 

 

 

560

 

Obligations under operating leases

 

 

2,355

 

 

 

2,700

 

Allowance for sales returns

 

 

4,285

 

 

 

3,644

 

Other current liabilities

 

 

14,241

 

 

 

17,697

 

Total current liabilities

 

 

31,589

 

 

 

34,478

 

Obligations under finance leases

 

 

108

 

 

 

366

 

Obligations under operating leases

 

 

3,320

 

 

 

4,086

 

Asset retirement obligations

 

 

212

 

 

 

211

 

Pension liability

 

 

8,136

 

 

 

7,840

 

Total liabilities

 

 

43,365

 

 

 

46,981

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock, $0.01 par value; 60,000 shares authorized: 45,788 and

   44,822 shares issued and outstanding at July 3, 2020 and

   January 3, 2020, respectively

 

 

458

 

 

 

448

 

Additional paid-in capital

 

 

320,235

 

 

 

304,288

 

Accumulated other comprehensive loss

 

 

(2,909

)

 

 

(3,048

)

Accumulated deficit

 

 

(143,110

)

 

 

(141,804

)

Total stockholders’ equity

 

 

174,674

 

 

 

159,884

 

Total liabilities and stockholders’ equity

 

$

218,039

 

 

$

206,865

 

 

See accompanying notes to the condensed consolidated financial statements.

 

1


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Net sales

 

$

35,194

 

 

$

39,664

 

 

$

70,381

 

 

$

72,247

 

Cost of sales

 

 

10,764

 

 

 

9,765

 

 

 

21,191

 

 

 

18,168

 

Gross profit

 

 

24,430

 

 

 

29,899

 

 

 

49,190

 

 

 

54,079

 

Selling, general and administrative expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

7,848

 

 

 

7,508

 

 

 

15,817

 

 

 

14,345

 

Marketing and selling

 

 

10,326

 

 

 

11,682

 

 

 

21,354

 

 

 

21,825

 

Research and development

 

 

7,311

 

 

 

6,098

 

 

 

14,209

 

 

 

11,733

 

Total selling, general and administrative expenses

 

 

25,485

 

 

 

25,288

 

 

 

51,380

 

 

 

47,903

 

Operating income (loss)

 

 

(1,055

)

 

 

4,611

 

 

 

(2,190

)

 

 

6,176

 

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

20

 

 

 

259

 

 

 

236

 

 

 

530

 

Gain (loss) on foreign currency transactions

 

 

388

 

 

 

11

 

 

 

(80

)

 

 

(237

)

Royalty income

 

 

52

 

 

 

163

 

 

 

146

 

 

 

334

 

Other income (expense), net

 

 

(21

)

 

 

1

 

 

 

(20

)

 

 

98

 

Total other income, net

 

 

439

 

 

 

434

 

 

 

282

 

 

 

725

 

Income (loss) before income taxes

 

 

(616

)

 

 

5,045

 

 

 

(1,908

)

 

 

6,901

 

Provision (benefit) for income taxes

 

 

556

 

 

 

1,131

 

 

 

(602

)

 

 

1,620

 

Net income (loss)

 

$

(1,172

)

 

$

3,914

 

 

$

(1,306

)

 

$

5,281

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.03

)

 

$

0.09

 

 

$

(0.03

)

 

$

0.12

 

Diluted

 

$

(0.03

)

 

$

0.08

 

 

$

(0.03

)

 

$

0.11

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

45,354

 

 

 

44,479

 

 

 

45,152

 

 

 

44,357

 

Diluted

 

 

45,354

 

 

 

46,733

 

 

 

45,152

 

 

 

46,842

 

 

See accompanying notes to the condensed consolidated financial statements.

2


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Net income (loss)

 

$

(1,172

)

 

$

3,914

 

 

$

(1,306

)

 

$

5,281

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Defined benefit plans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net change in plan assets

 

 

(28

)

 

 

(614

)

 

 

(53

)

 

 

(640

)

Reclassification into other income, net

 

 

72

 

 

 

28

 

 

 

142

 

 

 

54

 

Foreign currency translation loss

 

 

113

 

 

 

382

 

 

 

86

 

 

 

339

 

Tax effect

 

 

(40

)

 

 

(55

)

 

 

(36

)

 

 

(35

)

Other comprehensive income (loss), net of tax

 

 

117

 

 

 

(259

)

 

 

139

 

 

 

(282

)

Comprehensive income (loss)

 

$

(1,055

)

 

$

3,655

 

 

$

(1,167

)

 

$

4,999

 

 

See accompanying notes to the condensed consolidated financial statements.

 

3


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

Common

Stock Shares

 

 

Common

Stock Par

Value

 

 

Additional

Paid-In

Capital

 

 

Accumulated

Other

Compre-

hensive

Income

(Loss)

 

 

Accumulated

Deficit

 

 

Total

 

Balance, at April 3, 2020

 

 

45,105

 

 

$

451

 

 

$

309,480

 

 

$

(3,026

)

 

$

(141,938

)

 

$

164,967

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,172

)

 

 

(1,172

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

117

 

 

 

 

 

 

117

 

Common stock issued upon exercise of options

 

 

681

 

 

 

7

 

 

 

7,546

 

 

 

 

 

 

 

 

 

7,553

 

Stock-based compensation

 

 

 

 

 

 

 

 

3,209

 

 

 

 

 

 

 

 

 

3,209

 

Vested restricted stock

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, at July 3, 2020

 

 

45,788

 

 

$

458

 

 

$

320,235

 

 

$

(2,909

)

 

$

(143,110

)

 

$

174,674

 

Balance, at March 29, 2019

 

 

44,447

 

 

$

444

 

 

$

292,722

 

 

$

(1,343

)

 

$

(154,485

)

 

$

137,338

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,914

 

 

 

3,914

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(259

)

 

 

 

 

 

(259

)

Common stock issued upon exercise of options

 

 

52

 

 

 

1

 

 

 

486

 

 

 

 

 

 

 

 

 

487

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,855

 

 

 

 

 

 

 

 

 

2,855

 

Unvested restricted stock

 

 

11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested restricted stock

 

 

24

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, at June 28, 2019

 

 

44,534

 

 

$

445

 

 

$

296,063

 

 

$

(1,602

)

 

$

(150,571

)

 

$

144,335

 

 

See accompanying notes to the condensed consolidated financial statements.


4


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (CONTINUED)

(In thousands)

(Unaudited)

 

 

 

Six Months Ended

 

 

 

Common

Stock Shares

 

 

Common

Stock Par

Value

 

 

Additional

Paid-In

Capital

 

 

Accumulated

Other

Compre-

hensive

Income

(Loss)

 

 

Accumulated

Deficit

 

 

Total

 

Balance, at January 3, 2020

 

 

44,822

 

 

$

448

 

 

$

304,288

 

 

$

(3,048

)

 

$

(141,804

)

 

$

159,884

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,306

)

 

 

(1,306

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

139

 

 

 

 

 

 

139

 

Common stock issued upon exercise of options

 

 

877

 

 

 

9

 

 

 

9,548

 

 

 

 

 

 

 

 

 

9,557

 

Stock-based compensation

 

 

 

 

 

 

 

 

6,399

 

 

 

 

 

 

 

 

 

6,399

 

Vested restricted stock

 

 

89

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

1

 

Balance, at July 3, 2020

 

 

45,788

 

 

$

458

 

 

$

320,235

 

 

$

(2,909

)

 

$

(143,110

)

 

$

174,674

 

Balance, at December 28, 2018

 

 

44,195

 

 

$

442

 

 

$

289,584

 

 

$

(1,320

)

 

$

(156,280

)

 

$

132,426

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,281

 

 

 

5,281

 

Impact of the adoption of lease accounting standard

 

 

 

 

 

 

 

 

 

 

 

 

 

 

113

 

 

 

113

 

Impact of adoption of nonemployee share-based payment standard

 

 

 

 

 

 

 

 

(315

)

 

 

 

 

 

315

 

 

 

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(282

)

 

 

 

 

 

(282

)

Common stock issued upon exercise of options

 

 

126

 

 

 

1

 

 

 

1,109

 

 

 

 

 

 

 

 

 

1,110

 

Stock-based compensation

 

 

 

 

 

 

 

 

5,685

 

 

 

 

 

 

 

 

 

5,685

 

Unvested restricted stock

 

 

11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested restricted stock

 

 

202

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

2

 

Balance, at June 28, 2019

 

 

44,534

 

 

$

445

 

 

$

296,063

 

 

$

(1,602

)

 

$

(150,571

)

 

$

144,335

 

 

See accompanying notes to the condensed consolidated financial statements.

 

5


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(1,306

)

 

$

5,281

 

Adjustments to reconcile net income (loss) to net cash provided by

   operating activities:

 

 

 

 

 

 

 

 

Depreciation of property, plant, and equipment

 

 

1,518

 

 

 

1,983

 

Amortization of intangibles

 

 

17

 

 

 

17

 

Deferred income taxes

 

 

(1,369

)

 

 

393

 

Change in net pension liability

 

 

376

 

 

 

203

 

Loss on disposal of property and equipment

 

 

3

 

 

 

 

Stock-based compensation expense

 

 

5,839

 

 

 

5,220

 

Provision for sales returns and bad debts

 

 

605

 

 

 

(32

)

Inventory provision

 

 

816

 

 

 

787

 

Changes in working capital:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(8,409

)

 

 

(6,533

)

Inventories

 

 

(932

)

 

 

106

 

Prepayments, deposits, and other current assets

 

 

(2,172

)

 

 

(1,154

)

Accounts payable

 

 

297

 

 

 

563

 

Other current liabilities

 

 

(3,471

)

 

 

(2,626

)

Net cash provided by (used in) operating activities

 

 

(8,188

)

 

 

4,208

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Acquisition of property and equipment

 

 

(4,210

)

 

 

(4,601

)

Acquisition of patents and licenses

 

 

 

 

 

(30

)

Net cash used in investing activities

 

 

(4,210

)

 

 

(4,631

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Repayment of finance lease obligations

 

 

(346

)

 

 

(681

)

Repayment on line of credit

 

 

(508

)

 

 

(999

)

Proceeds from the exercise of stock options

 

 

9,557

 

 

 

1,110

 

Proceeds from vested restricted stock

 

 

1

 

 

 

2

 

Net cash provided by (used in) financing activities

 

 

8,704

 

 

 

(568

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

41

 

 

 

243

 

Decrease in cash, cash equivalents and restricted cash

 

 

(3,653

)

 

 

(748

)

Cash, cash equivalents and restricted cash, at beginning of the period

 

 

119,968

 

 

 

103,999

 

Cash, cash equivalents and restricted cash, at end of the period

 

$

116,315

 

 

$

103,251

 

 

See accompanying notes to the condensed consolidated financial statements.

 

6


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 1 — Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of the Company present the financial position, results of operations, and cash flows of STAAR Surgical Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in the Comprehensive Financial Statements have been condensed or omitted pursuant to such rules and regulations. The Consolidated Balance Sheet as of January 3, 2020 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended January 3, 2020.

The Condensed Consolidated Financial Statements for the three and six months ended July 3, 2020 and June 28, 2019, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and six months ended July 3, 2020 and June 28, 2019, are not necessarily indicative of the results to be expected for any other interim period or for the entire year.  

Each of the Company’s fiscal reporting periods ends on the Friday nearest to the quarter ending date and generally consists of 13 weeks.  Unless the context indicates otherwise “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries.

Vendor Concentration

There were two vendors which accounted for over 27% of the Company’s consolidated accounts payable as of July 3, 2020.  There was one vendor which accounted for over 11% of the Company’s consolidated accounts payable as of January 3, 2020.  There were no vendors who accounted for over 10% of the Company’s consolidated purchases for the three months ended July 3, 2020.  There were three vendors who accounted for over 43% of the Company’s consolidated purchases for the six months ended July 3, 2020.  

Use of Estimates

During the COVID-19 pandemic, the Company believes it has used reasonable estimates and assumptions in determining valuation allowances for uncollectible trade receivables, sales returns reserves, obsolete and excess inventory reserves, deferred income taxes, and tax reserves, including valuation allowances for deferred tax assets, pension liabilities, evaluation of asset impairment, in determining the useful life of depreciable and definite-lived intangible assets, and in the variables and assumptions used to calculate and record stock-based compensation.  During the quarter ended July 3, 2020, the Company has experienced some delays in customer payments but is unaware of any material impairment of customer receivables.  The Company’s sales representatives throughout the world remain engaged with customers conducting online training and other educational courses which have been very well attended.  This activity has given the Company insight as to the impact to customers of COVID-19 and potential impairment of receivables.

Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted

On January 4, 2020 (beginning of fiscal year 2020), the Company adopted Accounting Standards Update (“ASU”) 2016‑13, “Financial Instruments – Credit Losses (Topic 326):  Measurement of Credit Losses on Financial Instruments,” which (i) significantly changes the impairment model for most financial assets that are measured at amortized cost and certain other instruments from an incurred loss model to an expected loss model; and (ii) provides for recording credit losses on available-for-sale debt securities through an allowance account.  ASU 2016-13 also requires certain incremental disclosures.  Subsequently, the FASB issued ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2020-02 and ASU 2020-03 to clarify and improve ASU 2016-13.  The adoption of ASU 2016-13 did not have a material impact on the Condensed Consolidated Financial Statements.

On January 4, 2020 (beginning of fiscal year 2020), the Company adopted ASU 2018-13, “Fair Value Measurement (Topic 820):  Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement,” which modifies certain disclosures requirements for reporting fair value measurements.  The adoption of ASU 2018-13 did not have a material impact on the Condensed Consolidated Financial Statements.

7


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 1 — Basis of Presentation and Significant Accounting Policies (Continued)

Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted (Continued)

On January 4, 2020 (beginning of fiscal year 2020), the Company adopted ASU 2018-14, “Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20); Disclosure Framework – Changes in the Disclosure Requirement for Defined Benefit Plans,” which modifies disclosure requirements for employers that sponsor defined benefit pension or other post retirement plans.  The adoption of ASU 2018-14 did not have a material impact on the Condensed Consolidated Financial Statements.

In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740):  Simplifying the Accounting for Income Taxes.” ASU 2019-12 removes the following exceptions:  exception to the incremental approach for intra period tax allocation; exception to accounting for basis differences when there are ownership changes in foreign investments; and exception to interim period tax accounting for year to date losses that exceed anticipated losses.  ASU 2019-12 also improves financial reporting for franchise taxes that are partially based on income; transactions with a government that result in a step up in the tax basis of goodwill; separate financial statements of legal entities that are not subject to tax; and enacted changes in tax laws in interim periods.  ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years.  Early adoption is permitted.  The Company will adopt this standard as of January 2, 2021 (beginning of fiscal year 2021) and is currently evaluating the disclosure requirements and its effect on the Condensed Consolidated Financial Statements.

Note 2 — Inventories

Inventories, net are stated at the lower of cost and net realizable value, determined on a first-in, first-out basis and consisted of the following (in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Raw materials and purchased parts

 

$

1,606

 

 

$

3,334

 

Work in process

 

 

4,997

 

 

 

1,870

 

Finished goods

 

 

12,487

 

 

 

12,976

 

Total inventories, gross

 

 

19,090

 

 

 

18,180

 

Less inventory reserves

 

 

1,254

 

 

 

1,038

 

Total inventories, net

 

$

17,836

 

 

$

17,142

 

 

Note 3 — Prepayments, Deposits, and Other Current Assets

Prepayments, deposits, and other current assets consisted of the following (in thousands):

 

 

July 3, 2020

 

 

January 3, 2020

 

Prepayments and deposits

 

$

5,106

 

 

$

3,031

 

Prepaid insurance

 

 

726

 

 

 

1,488

 

Consumption tax receivable

 

 

661

 

 

 

875

 

Value added tax (VAT) receivable

 

 

1,313

 

 

 

713

 

BVG (Swiss Pension) prepayment

 

 

451

 

 

 

 

Other(1)

 

 

640

 

 

 

453

 

Total prepayments, deposits and other current assets

 

$

8,897

 

 

$

6,560

 

 

(1)

No individual item in “other current assets” exceeds 5% of the total prepayments, deposits and other current assets.

8


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 4 — Property, Plant and Equipment

Property, plant and equipment, net consisted of the following (in thousands):

 

 

July 3, 2020

 

 

January 3, 2020

 

Machinery and equipment

 

$

20,970

 

 

$

17,173

 

Computer equipment and software

 

 

6,593

 

 

 

6,244

 

Furniture and fixtures

 

 

4,561

 

 

 

4,169

 

Leasehold improvements

 

 

11,100

 

 

 

10,151

 

Construction in process

 

 

8,889

 

 

 

8,477

 

Total property, plant and equipment, gross

 

 

52,113

 

 

 

46,214

 

Less accumulated depreciation

 

 

30,635

 

 

 

29,149

 

Total property, plant and equipment, net

 

$

21,478

 

 

$

17,065

 

 

Note 5 –Intangible Assets

Intangible assets, net consisted of the following (in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Long-lived amortized intangible assets

 

Gross

Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net

 

 

Gross

Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net

 

Patents and licenses

 

$

9,356

 

 

$

(9,076

)

 

$

280

 

 

$

9,353

 

 

$

(9,057

)

 

$

296

 

 

Note 6 – Other Current Liabilities

Other current liabilities consisted of the following (in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Accrued salaries and wages

 

$

5,752

 

 

$

4,400

 

Accrued bonuses

 

 

 

 

 

4,184

 

Accrued insurance

 

 

372

 

 

 

1,346

 

Income taxes payable

 

 

2,579

 

 

 

2,710

 

Accrued consumption tax

 

 

750

 

 

 

1,164

 

Accrued professional fees for clinical trials

 

 

968

 

 

 

567

 

Marketing obligations

 

 

838

 

 

 

633

 

Other(1)

 

 

2,982

 

 

 

2,693

 

Total other current liabilities

 

$

14,241

 

 

$

17,697

 

 

(1)

No individual item in “Other” exceeds 5% of the other current liabilities.

Note 7 – Lines of Credit

Since 1998, the Company’s wholly owned Japanese subsidiary, STAAR Japan, has had an agreement with Mizuho Bank which provides for borrowings of up to 500,000,000 Yen, at an interest rate equal to the uncollateralized overnight call rate (approximately 0.06% as of July 3, 2020) plus a 0.50% spread, and may be renewed quarterly (the current line expires on August 21, 2020).  The credit facility is not collateralized.  The Company had 142,500,000 Yen and 197,500,000 Yen outstanding on the line of credit as of July 3, 2020 and January 3, 2020, respectively (approximately $1,325,000 and $1,827,000 based on the foreign exchange rates on July 3, 2020 and January 3, 2020, respectively), which approximates fair value due to the short-term maturity and market interest rates of the line of credit.  In case of default, the interest rate will be increased to 14% per annum.  There was 357,500,000 Yen and 302,500,000 Yen available for borrowing as of July 3, 2020 and  January 3, 2020, respectively (approximately $3,325,000 and $2,798,000 based on the foreign exchange rate on July 3, 2020 and January 3, 2020, respectively).  At maturity on August 21, 2020, the Company expects to renew this line of credit for an additional three months, with similar terms.

9


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 7 – Lines of Credit (Continued)

In September 2013, the Company’s wholly owned Swiss subsidiary, STAAR Surgical AG, entered into a framework agreement for loans (“framework agreement”) with Credit Suisse (the “Bank”). The framework agreement provides for borrowings of up to 1,000,000 CHF (Swiss Francs) (approximately $1,100,000 and $1,000,000 at the rate of exchange on July 3, 2020 and January 3, 2020 respectively), to be used for working capital purposes. Accrued interest and 0.25% commissions on average outstanding borrowings is payable quarterly and the interest rate will be determined by the Bank based on the then prevailing market conditions at the time of borrowing. The framework agreement is automatically renewed on an annual basis based on the same terms assuming there is no default. The framework agreement may be terminated by either party at any time in accordance with its general terms and conditions. The framework agreement is not collateralized and contains certain conditions such as providing the Bank with audited financial statements annually and notice of significant events or conditions, as defined in the framework agreement. The Bank may also declare all amounts outstanding to be immediately due and payable upon a change of control or a “material qualification” in STAAR Surgical independent auditors’ report, as defined. There were 0 borrowings outstanding as of July 3, 2020 and January 3, 2020.

The Company is in compliance with covenants of its credit facilities and lines of credit as of July 3, 2020.

Note 8 – Leases

Finance Leases

The Company entered into finance leases primarily related to purchases of equipment used for manufacturing or computer-related equipment.  These finance leases are two to five years in length and have fixed payment amounts for the term of the contract and have options to purchase the assets at the end of the lease term.  Supplemental balance sheet information related to finance leases consisted of the following (dollars in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Machinery and equipment

 

$

568

 

 

$

1,885

 

Computer equipment and software

 

 

860

 

 

 

912

 

Furniture and fixtures

 

 

 

 

 

102

 

Leasehold improvements

 

 

 

 

 

27

 

Finance lease right-of-use assets, gross

 

 

1,428

 

 

 

2,926

 

Less accumulated depreciation

 

 

741

 

 

 

1,059

 

Finance lease right-of-use assets, net

 

$

687

 

 

$

1,867

 

 

 

 

 

 

 

 

 

 

Total finance lease liability

 

$

601

 

 

$

926

 

Weighted-average remaining lease term (in years)

 

 

2.0

 

 

 

1.1

 

Weighted-average discount rate

 

 

5.40

%

 

 

6.17

%

 

Supplemental cash flow information related to finance leases consisted of the following (dollars in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Amortization of finance lease right-of-use asset

 

$

50

 

 

$

145

 

 

$

167

 

 

$

306

 

Interest on finance lease liabilities

 

 

8

 

 

 

22

 

 

 

18

 

 

 

41

 

Cash paid for amounts included in the measurement of finance lease liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating cash flows

 

 

8

 

 

 

22

 

 

 

18

 

 

 

41

 

Financing cash flows

 

 

110

 

 

 

316

 

 

 

346

 

 

 

681

 

Right-of-use assets obtained in exchange for new finance lease liabilities

 

 

22

 

 

 

37

 

 

 

22

 

 

 

679

 

10


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 8 – Leases (Continued)

Operating Leases

The Company entered into operating leases primarily related to real property (office, manufacturing and warehouse facilities), automobiles and copiers.  These operating leases are two to five years in length with options to extend.  The Company did not include any lease extensions in the initial valuation unless the Company was reasonably certain to extend the lease.  Depending on the lease, there are those with fixed payment amounts for the entire length of the contract or payments which increase periodically as noted in the contract or increased at an inflation rate indicator.  For operating leases that increase using an inflation rate indicator, the Company used the inflation rate at the time the lease was entered into for the length of the lease term.  Supplemental balance sheet information related to operating leases consisted of the following (dollars in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Machinery and equipment

 

$

837

 

 

$

765

 

Computer equipment and software

 

 

462

 

 

 

462

 

Real property

 

 

11,247

 

 

 

11,116

 

Operating lease right-of-use assets, gross

 

 

12,546

 

 

 

12,343

 

Less accumulated depreciation

 

 

6,959

 

 

 

5,659

 

Operating lease right-of-use assets, net

 

$

5,587

 

 

$

6,684

 

 

 

 

 

 

 

 

 

 

Total operating lease liability

 

$

5,675

 

 

$

6,786

 

Weighted-average remaining lease term (in years)

 

 

2.2

 

 

 

2.3

 

Weighted-average discount rate

 

 

1.75

%

 

 

1.82

%

 

Supplemental cash flow information related to operating leases was as follows (dollars in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Operating lease cost

 

$

746

 

 

$

683

 

 

$

1,486

 

 

$

1,294

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating cash flows

 

 

763

 

 

 

691

 

 

 

1,501

 

 

 

1,292

 

Right-of-use assets obtained in exchange for new operating lease liabilities

 

 

249

 

 

 

1,193

 

 

 

318

 

 

 

2,657

 

Future Minimum Lease Commitments

Estimated future minimum lease payments under operating and finance leases having initial or remaining non-cancelable lease terms more than one year as of July 3, 2020 is as follows (in thousands):

 

As of July 3, 2020

12 Months Ended

 

Operating Leases

 

 

Finance Leases

 

June 2021

 

$

2,473

 

 

$

510

 

June 2022

 

 

1,394

 

 

 

84

 

June 2023

 

 

1,216

 

 

 

14

 

June 2024

 

 

665

 

 

 

11

 

June 2025

 

 

171

 

 

 

 

Thereafter

 

 

 

 

 

 

Total minimum lease payments, including interest

 

$

5,919

 

 

$

619

 

Less amounts representing interest

 

 

244

 

 

 

18

 

Total minimum lease payments

 

$

5,675

 

 

$

601

 

 

11


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 9 Income Taxes

The Company recorded an income tax provision (benefit) as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Provision (benefit) for income taxes

 

$

556

 

 

$

1,131

 

 

$

(602

)

 

$

1,620

 

The Company recorded income taxes of $556,000 and $1,131,000 for the three months ended July 3, 2020 and June 28, 2019, respectively, primarily due to pre-tax income generated in certain foreign jurisdictions.  Also included in the three months ended June 28, 2019 were withholding taxes on foreign operations.  The Company recorded an income tax benefit of $602,000 for the six months ended July 3, 2020 due to the income tax benefit from the release of its U.S. valuation allowance, offset by income tax expense from profits generated from its foreign operations.  The Company recorded income taxes of $1,620,000 for the six months ended June 28, 2019, primarily due to pre-tax income generated in certain foreign jurisdictions and withholding taxes on foreign operations.  The Company’s quarterly provision for income taxes is determined by estimating an annual effective tax rate.  This estimate may fluctuate throughout the year as new information becomes available affecting its underlying assumptions.  In the fourth quarter of fiscal year 2019, the Company reversed all previously recorded withholding taxes recorded for 2019, at which time the Company formed STAAR Surgical UK Limited as a holding company for its foreign operations.  Based on the current tax treaties between the U.S., United Kingdom and Switzerland, the Company will no longer accrue for Switzerland withholding taxes on foreign earnings after fiscal 2018 (see also Note 10 in its fiscal 2019 Form 10-K for more information). There are 0 unrecognized tax benefits related to uncertain tax positions taken by the Company.   All earnings from the Company’s subsidiaries are not considered to be permanently reinvested.

The 2017 Tax Act subjects a U.S. shareholder to tax on Global Intangible Low Tax Income (“GILTI”) earned by certain foreign subsidiaries.  In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets.  The provision further allows a deduction of 50 percent of GILTI, however this deduction is limited by the Company’s U.S. taxable income.  The Company has elected to account for GILTI as a current period expense when incurred.

For the three and six months ended July 3, 2020, the Company included GILTI of $4,137,000 and $5,400,000, respectively, and for the three and six months ended June 28, 2019, included GILTI of $5,635,000 and $7,699,000, respectively, in U.S. gross income, which was fully offset by net operating loss carryforwards.  The Company was not able to utilize the deduction of 50 percent of GILTI, as this deduction is limited by the Company’s pre-GILTI U.S. taxable income.

The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the projected future income and tax planning strategies in making this assessment. As of fiscal year end 2019, the Company had three years of accumulated profits for federal income tax purposes as a result of GILTI.  However, the three-year income position is not solely determinative and, accordingly, management considers all other available positive and negative evidence in its analysis. This includes existing profits in foreign jurisdiction as well as projected future profits. As further described in Notes 1 and 10 of the Company’s fiscal 2019 Form 10-K, under the “incremental cash tax savings approach,” the Company recorded a valuation allowance release of $3,003,000 and $373,000 against the federal and certain states deferred tax assets, respectively.  During the six months ended July 3, 2020, the Company revised its global forecasts as a result of COVID-19, and released an additional $1,369,000 of valuation allowance.  As of July 3, 2020, the Company released approximately $4,745,000 of valuation allowance on its deferred tax assets in the U.S. jurisdiction utilizing the incremental cash tax savings approach.

Under the incremental cash tax savings approach, the U.S. valuation allowances of $36,530,000, will remain as the usage of the remaining net operating losses and deferred tax assets will not result in cash tax savings and therefore provide no additional benefit.  As of July 3, 2020, the Company had net deferred tax assets in the U.S. of $4,881,000, which consisted of the federal and state valuation allowance release of $4,439,000 and $306,000, respectively, and the refundable alternative minimum tax credit of $136,000.  

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law.  The Company reviewed the provisions of the CARES Act, but does not expect it to have a material impact to its tax provision (also see note 15). 

12


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 9 Income Taxes (Continued)

On July 20, the U.S. Treasury issued final regulations for addressing the treatment of foreign income that is subject to a high rate of foreign tax (the GILTI high-tax exclusion). The final regulations allow companies to exclude certain high-taxed income from their GILTI calculation.  The GILTI high-tax exclusion applies if the effective foreign tax rate is 90% or more of the rate that would apply if the income were subject to the maximum US rate of tax specified in section 11 (currently 18.9%, based on a maximum rate of 21%).  The final regulations also provide that the GILTI high-tax exclusion is an annual election made each year and is retroactive to years beginning after December 31, 2017.  As the regulations were finalized on July 20, 2020, after the current reporting period, the impact if any on the financial statements will be reported in the third quarter.  Management is currently evaluating the effect if any this election would have on their financial statements.

Note 10 – Defined Benefit Pension Plans

 

The Company has defined benefit plans covering employees of its Switzerland and Japan operations.  The following table summarizes the components of net periodic pension cost recorded for the Company’s defined benefit pension plans (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Service cost(1)

 

$

320

 

 

$

248

 

 

$

639

 

 

$

480

 

Interest cost(2)

 

 

11

 

 

 

20

 

 

 

22

 

 

 

40

 

Expected return on plan assets(2)

 

 

(46

)

 

 

(34

)

 

 

(89

)

 

 

(67

)

Prior service credit(2),(3)

 

 

(8

)

 

 

(5

)

 

 

(17

)

 

 

(11

)

Actuarial loss recognized in current period(2),(3)

 

 

80

 

 

 

33

 

 

 

159

 

 

 

65

 

Net periodic pension cost

 

$

357

 

 

$

262

 

 

$

714

 

 

$

507

 

 

(1)

Recognized in selling general and administrative expenses on the Condensed Consolidated Statements of Income.

(2)

Recognized in other income (expense), net on the Condensed Consolidated Statements of Income.

(3)

Amounts reclassified from accumulated other comprehensive income (loss).

 

The Company currently is not required to and does not make contributions to its Japan pension plan.  The Company’s contributions to its Swiss pension plan are as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Employer contribution

 

$

155

 

 

$

137

 

 

$

330

 

 

$

263

 

 

13


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 11 — Stockholders’ Equity

Stock-Based Compensation

The cost that has been charged against income for stock-based compensation is set forth below (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Employee stock options

 

$

2,505

 

 

$

2,162

 

 

$

4,737

 

 

$

3,592

 

Restricted stock

 

 

76

 

 

 

77

 

 

 

154

 

 

 

159

 

Restricted stock units

 

 

274

 

 

 

311

 

 

 

823

 

 

 

1,415

 

Nonemployee stock options

 

 

63

 

 

 

29

 

 

 

125

 

 

 

54

 

Total stock-based compensation expense

 

$

2,918

 

 

$

2,579

 

 

$

5,839

 

 

$

5,220

 

 

The Company recorded stock-based compensation costs in the following categories (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Cost of sales

 

$

30

 

 

$

22

 

 

$

52

 

 

$

36

 

General and administrative

 

 

1,209

 

 

 

1,018

 

 

 

2,294

 

 

 

1,796

 

Marketing and selling

 

 

812

 

 

 

690

 

 

 

1,867

 

 

 

1,861

 

Research and development

 

 

867

 

 

 

849

 

 

 

1,626

 

 

 

1,527

 

Total stock-based compensation expense, net

 

 

2,918

 

 

 

2,579

 

 

 

5,839

 

 

 

5,220

 

Amounts capitalized as part of inventory

 

 

291

 

 

 

276

 

 

 

560

 

 

 

465

 

Total stock-based compensation expense, gross

 

$

3,209

 

 

$

2,855

 

 

$

6,399

 

 

$

5,685

 

 

Incentive Plan

The Amended and Restated Omnibus Equity Incentive Plan (“the Plan”) provides for various forms of stock-based incentives. To date, of the available forms of awards under the Plan, the Company has granted only stock options, restricted stock, unrestricted share grants, and restricted stock units (“RSUs”). Options under the Plan are granted at fair market value on the date of grant, become exercisable generally over a three-year period, or as determined by the Board of Directors, and expire over periods not exceeding 10 years from the date of grant. Certain option and share awards provide for accelerated vesting if there is a change in control and pre-established financial metrics are met (as defined in the Plan). Grants of restricted stock outstanding under the Plan generally vest over periods of one to three years. Grants of RSUs outstanding under the Plan generally vest based on service, performance, or a combination of both.  As of July 3, 2020, there were 842,975 shares available for grant under the Plan

Assumptions

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model applying the weighted-average assumptions noted in the following table.  Expected volatilities are based on historical volatility of the Company’s stock. The expected term of options granted is derived from the historical exercises and post-vesting cancellations and represents the period of time that options granted are expected to be outstanding.  The Company has calculated an 6% estimated forfeiture rate based on historical forfeiture experience.  The risk-free rate is based on the U.S. Treasury yield curve corresponding to the expected term at the time of the grant.  

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Expected dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

 

 

0

%

Expected volatility

 

 

53

%

 

 

53

%

 

 

53

%

 

 

53

%

Risk-free interest rate

 

 

0.31

%

 

 

2.05

%

 

 

0.53

%

 

 

2.41

%

Expected term (in years)

 

 

5.72

 

 

 

5.67

 

 

 

5.72

 

 

 

5.67

 

 

14


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 11 — Stockholders’ Equity (Continued)

Stock Options

A summary of stock option activity under the Plan for the six months ended July 3, 2020 is presented below:

 

 

 

Stock

Options

(in 000’s)

 

 

Minimum

Exercise

Price

 

 

Maximum

Exercise

Price

 

Outstanding at January 3, 2020

 

 

4,326

 

 

 

 

 

 

 

 

 

Granted

 

 

609

 

 

 

 

 

 

 

 

 

Exercised

 

 

(876

)

 

 

 

 

 

 

 

 

Forfeited or expired

 

 

(12

)

 

 

 

 

 

 

 

 

Outstanding at July 3, 2020

 

 

4,047

 

 

$

5.05

 

 

$

43.84

 

Exercisable at July 3, 2020

 

 

2,717

 

 

 

 

 

 

 

 

 

 

Restricted Stock and Restricted Stock Units

A summary of restricted stock and RSU activity under the Plan for the six months ended July 3, 2020 is presented below:

 

 

 

Restricted

Stock

(in 000’s)

 

 

Restricted

Stock

Units

(in 000’s)

 

Unvested at January 3, 2020

 

 

11

 

 

 

104

 

Granted

 

 

 

 

 

97

 

Vested

 

 

(11

)

 

 

(89

)

Forfeited or expired

 

 

 

 

 

(1

)

Unvested at July 3, 2020

 

 

 

 

 

111

 

 

Note 12 - Commitments and Contingencies

Litigation and Claims

From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business.  These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability.  STAAR maintains insurance coverage for various matters, including product liability and certain securities claims.  While the Company does not believe that any of the claims known is likely to have a material adverse effect on the Company’s financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm.

Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all its assets, or termination “without cause or for good reason” as defined in the employment agreements.

15


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 13 — Basic and Diluted Net Income (Loss) Per Share

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share amounts):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(1,172

)

 

$

3,914

 

 

$

(1,306

)

 

$

5,281

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares outstanding

 

 

45,354

 

 

 

44,489

 

 

 

45,152

 

 

 

44,368

 

Less:  Unvested restricted stock

 

 

 

 

 

(10

)

 

 

 

 

 

(11

)

Denominator for basic calculation

 

 

45,354

 

 

 

44,479

 

 

 

45,152

 

 

 

44,357

 

Weighted average effects of potentially diluted common stock:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock options

 

 

 

 

 

2,149

 

 

 

 

 

 

2,292

 

Unvested restricted stock

 

 

 

 

 

97

 

 

 

 

 

 

185

 

Restricted stock units

 

 

 

 

 

8

 

 

 

 

 

 

8

 

Denominator for diluted calculation

 

 

45,354

 

 

 

46,733

 

 

 

45,152

 

 

 

46,842

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.03

)

 

$

0.09

 

 

$

(0.03

)

 

$

0.12

 

Diluted

 

$

(0.03

)

 

$

0.08

 

 

$

(0.03

)

 

$

0.11

 

Because the Company had a net loss for the three and six months ended July 3, 2020, the number of diluted shares is equal to the number of basic shares.  The following table sets forth (in thousands) the weighted average number of options to purchase shares of common stock, restricted stock, and restricted stock units with either exercise prices or unrecognized compensation cost per share greater than the average market price per share of the Company’s common stock, which were not included in the calculation of diluted per share amounts because the effects would be anti-dilutive.

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Stock options

 

 

3,082

 

 

 

1,991

 

 

 

3,502

 

 

 

1,256

 

Restricted stock and restricted stock units

 

 

59

 

 

 

1

 

 

 

72

 

 

 

 

Total

 

 

3,141

 

 

 

1,992

 

 

 

3,574

 

 

 

1,256

 

 

16


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 14 — Disaggregation of Sales, Geographic Sales and Product Sales

In the following tables, sales are disaggregated by category, sales by geographic market and sales by product data.  The following breaks down sales into the following categories (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Non-consignment sales

 

$

23,446

 

 

$

35,556

 

 

$

53,846

 

 

$

63,822

 

Consignment sales

 

 

11,748

 

 

 

4,108

 

 

 

16,535

 

 

 

8,425

 

Total net sales

 

$

35,194

 

 

$

39,664

 

 

$

70,381

 

 

$

72,247

 

 

The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States.  Other than China and Japan, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Domestic

 

$

882

 

 

$

2,114

 

 

$

2,621

 

 

$

4,066

 

Foreign:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

China

 

 

18,603

 

 

 

19,394

 

 

 

30,318

 

 

 

31,165

 

Japan

 

 

7,463

 

 

 

6,275

 

 

 

15,765

 

 

 

11,794

 

Other(1)

 

 

8,246

 

 

 

11,881

 

 

 

21,677

 

 

 

25,222

 

Total foreign sales

 

 

34,312

 

 

 

37,550

 

 

 

67,760

 

 

 

68,181

 

Total net sales

 

$

35,194

 

 

$

39,664

 

 

$

70,381

 

 

$

72,247

 

 

(1)

No other location individually exceeds 10% of the total sales.

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as 1 operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery.  The composition of the Company’s net sales by product line was as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

ICLs

 

$

30,728

 

 

$

34,432

 

 

$

60,068

 

 

$

62,218

 

Other product sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IOLs

 

 

2,561

 

 

 

3,874

 

 

 

6,555

 

 

 

7,891

 

Other surgical products

 

 

1,905

 

 

 

1,358

 

 

 

3,758

 

 

 

2,138

 

Total other product sales

 

 

4,466

 

 

 

5,232

 

 

 

10,313

 

 

 

10,029

 

Total net sales

 

$

35,194

 

 

$

39,664

 

 

$

70,381

 

 

$

72,247

 

 

One customer, the Company’s distributor in China, accounted for 53% and 43% of net sales for the three and six months ended July 3, 2020, respectively, and the same customer, accounted for 49% and 43% of net sales for the three and six months ended June 28, 2019, respectively.  As of July 3, 2020 and January 3, 2020, respectively, one customer, the Company’s distributor in China, accounted for 57% and 43% of consolidated trade receivables.

17


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 15 — COVID-19 and CARES Act Developments

 

In December 2019, COVID-19 surfaced and in March 2020, the World Health Organization declared a pandemic related to the rapid spread of COVID-19 around the world.  The impact of the COVID-19 outbreak on the businesses and the economy in the U.S. and the rest of the world is, and is expected to continue to be, uncertain and may be significant. Accordingly, the Company cannot predict the extent to which its financial condition and results of operation will be affected. On March 17, 2020, the Company suspended most of its production and non-essential business locations where employees can work from home.  A very limited number of manufacturing personnel remained at work for critical late staged processes, until the end of March 2020.  Manufacturing resumed on April 27, 2020.  The Company’s revenues have been adversely impacted, as customers in China were not able to carry out procedures during the month of February and the Company experienced a substantial slowdown in sales beginning March 20, 2020 in global geographies characterized as “hot spots” for the COVID 19 virus, including parts of Europe and North America.  In certain of these markets, sales have paused as elective surgeries are discouraged to support COVID-19 related needs.  The Company expects decreases in sales in certain geographies to continue through the remainder of 2020 as different geographies resume business activities on differing timelines.  

 

The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.  The Company did not apply for or require financing available under the CARES Act and does not expect to do so given the strength of our balance sheet.  The Company will continue to monitor the impact that the CARES Act may have on its business, financial condition, results of operations, or liquidity.

 

18


 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products (including the EVO family of lenses in the U.S. and the EDOF ICL for presbyopia internationally); commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2020 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.

Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, risks and uncertainties related to the COVID-19 pandemic and related public health measures, and those described in in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 26, 2020, as well as the updated risk factor disclosed herein.  We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.

The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.

Overview

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (IOL) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our IOL lenses used in surgery that treats cataracts based on quality and value.

 

Recent Developments

While refractive procedures were down significantly or came to a halt in April and May in much of North America, Europe, Latin America, India and the Middle East, continuing recovery and growth were recorded in Japan, Korea and China.  The positive trending continued in July with China experiencing stronger than anticipated demand as the peak season began in earnest.  While COVID-19 hotspots and government public health mandates may reoccur moving forward, we anticipate less business interruption and continued increased interest in our EVO ICL lens-based refractive solutions in the third and fourth quarter of 2020. We also continue to believe that we will achieve a 20% share of the refractive procedure market in China by the end of the year. Assuming significant COVID-19 hotspots and government public health mandates do not reoccur and global economic improvement progresses, our outlook for the third quarter of 2020 currently anticipates a sequential revenue increase of over 20% from our second quarter of 2020 results which would then result in year-over-year double digit growth.  Also, we currently expect fourth quarter of 2020 revenue will be similar to third quarter of 2020.

19


 

We resumed production at our California manufacturing facilities on April 27, 2020 and anticipate that we will be able to meet the demand for both our Spheric and Toric EVO lenses through the remainder of 2020.  We are moving forward with our plans to restart manufacturing in our Nidau, Switzerland facility in 2021. With respect to our U.S. clinical trial for our EVO family of myopia lenses, assuming no material change in the current operating environment we anticipate that we will complete enrollment in the trial by the end of September.  Considering the subsequent six-month patient follow-up and time to prepare our data submission to the FDA, we believe we are on track for potential marketing approval and commercialization of EVO in the U.S. in the second half of 2021.

As previously disclosed, we received on July 2, 2020, CE Mark approval for our extended depth of focus or EDOF presbyopia lens, EVO Viva, that is designed to correct near, intermediate and distance vision. We will commence a phased-rollout beginning in Spain, Belgium and Germany. We anticipate the first implants will occur in September following physician training and certification.

Critical Accounting Policies

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.

An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the six months ended July 3, 2020 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended January 3, 2020.

Results of Operations

The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Operations for the periods indicated.

 

 

 

Percentage of Net Sales

for Three Months

 

 

Percentage of Net Sales

for Six Months

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Net sales

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

Cost of sales

 

 

30.6

%

 

 

24.6

%

 

 

30.1

%

 

 

25.1

%

Gross profit

 

 

69.4

%

 

 

75.4

%

 

 

69.9

%

 

 

74.9

%

General and administrative

 

 

22.3

%

 

 

18.9

%

 

 

22.5

%

 

 

19.9

%

Marketing and selling

 

 

29.3

%

 

 

29.5

%

 

 

30.3

%

 

 

30.2

%

Research and development

 

 

20.8

%

 

 

15.4

%

 

 

20.2

%

 

 

16.3

%

Total selling, general and administrative

 

 

72.4

%

 

 

63.8

%

 

 

73.0

%

 

 

66.4

%

Operating income (loss)

 

 

(3.0

)%

 

 

11.6

%

 

 

(3.1

)%

 

 

8.5

%

Total other income (expense), net

 

 

1.2

%

 

 

1.1

%

 

 

0.4

%

 

 

1.0

%

Income (loss) before income taxes

 

 

(1.8

)%

 

 

12.7

%

 

 

(2.7

)%

 

 

9.5

%

Provision (benefit) for income taxes

 

 

1.5

%

 

 

2.9

%

 

 

(0.8

)%

 

 

2.2

%

Net income (loss)

 

 

(3.3

)%

 

 

9.8

%

 

 

(1.9

)%

 

 

7.3

%

 

20


 

Net Sales

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

ICLs

 

$

30,728

 

 

$

34,432

 

 

 

(10.8

)%

 

$

60,068

 

 

$

62,218

 

 

 

(3.5

)%

Other product sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IOLs

 

 

2,561

 

 

 

3,874

 

 

 

(33.9

)%

 

 

6,555

 

 

 

7,891

 

 

 

(16.9

)%

Other surgical products

 

 

1,905

 

 

 

1,358

 

 

 

40.3

%

 

 

3,758

 

 

 

2,138

 

 

 

75.8

%

Total other product sales

 

 

4,466

 

 

 

5,232

 

 

 

(14.6

)%

 

 

10,313

 

 

 

10,029

 

 

 

2.8

%

Net sales

 

$

35,194

 

 

$

39,664

 

 

 

(11.3

)%

 

$

70,381

 

 

$

72,247

 

 

 

(2.6

)%

 

Net sales for the three months ended July 3, 2020 were $35.2 million, a decrease of 11% from $39.7 million reported during the same period of 2019.  The decrease in net sales was due to decreases in ICL sales of $3.7 million and other product sales of $0.8 million.  

Net sales for the six months ended July 3, 2020 were $70.4 million, a decrease of 3% from $72.2 million reported during the same period of 2019.  The decrease in net sales was due to a decrease in ICL sales of $2.2 million, partially offset by an increase in other product sales of $0.3 million.

Total ICL sales for the three months ended July 3, 2020 were $30.7 million, a decrease of 11% from $34.4 million reported for the same period of 2019, with unit decrease of 3%. The Europe, Middle East, Africa and Latin America region sales decreased 30% with unit decrease of 31%.  The North America region sales decreased 55%, with unit decrease of 56%.  The decrease in both these regions were impacted by the COVID-19 pandemic when markets started to reopen in mid-May/early June.  The APAC region sales decreased by 2%, with unit growth up 5% due to unit growth in Japan up 39%, Korea up 16% and China up 6%. ICL sales represented 87.3% and 86.8% of our total sales for the three months ended July 3, 2020 and June 28, 2019, respectively.

Total ICL sales for the six months ended July 3, 2020 were $60.1 million, a 4% decrease from $62.2 million reported for the same period of 2019, with unit growth up 2%. The Europe, Middle East, Africa and Latin America region sales and units decreased 17%.  The North America region sales and units decreased 32%.  The decrease in both these regions were impacted by the COVID-19 pandemic when markets started to reopen in mid-May/early June.  The APAC region sales increased by 3%, with unit growth up 8% due to unit growth in Japan up 58%, Korea up 15% and China up 7%.  ICL sales represented 85.3% and 86.1% of our total sales for the six months ended July 3, 2020 and June 28, 2019, respectively.

Other product sales, including IOLs were $4.5 million for the three months ended July 3, 2020, a decrease of 15% from $5.2 million reported for the same period of 2019.  The decrease is due to a decrease in IOL sales, partially offset by an increase in preloaded injector part sales to a third-party manufacturer for product they sell to their customers.  Other product sales were $10.3 million for the six months ended July 3, 2020, an increase of 3% from $10.0 million reported for the same period of 2019.  The increase is due to an increase in preloaded injector part sales to a third-party manufacturer for product they sell to their customers, offset by a decrease in IOL sales.  Other product sales represented 12.7% and 13.2% of our total sales for the three months ended July 3, 2020 and June 28, 2019, respectively, and represented 14.7% and 13.9% of our total sales for the six months ended July 3, 2020 and June 28, 2019, respectively.

Gross Profit

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Gross profit

 

$

24,430

 

 

$

29,899

 

 

 

(18.3

)%

 

$

49,190

 

 

$

54,079

 

 

 

(9.0

)%

Gross margin

 

 

69.4

%

 

 

75.4

%

 

 

 

 

 

 

69.9

%

 

 

74.9

%

 

 

 

 

 

Gross profit for the three months ended July 3, 2020 was $24.4 million, an 18.3% decrease compared to the $29.9 million reported for the same period of 2019.  Gross profit margin decreased to 69.4% of revenue for the three months ended July 3, 2020 compared to 75.4% of revenue for the three months ended June 28, 2019, due to geographic sales mix, $1.0 million in expenses related to the COVID-19 manufacturing pause from April 4 through April 27, 2020, period costs associated with the manufacturing expansion projects, and increased mix of injector part sales which carry a lower margin.  

21


 

Gross profit for the six months ended July 3, 2020 was $49.2 million, a 9.0% decrease compared to the $54.1 million reported for the same period of 2019.  Gross profit margin decreased to 69.9% of revenue for the six months ended July 3, 2020 compared to 74.9% of revenue for the three months ended June 28, 2019, due primarily to geographic sales mix, $1.2 million in expenses related to the COVID-19 manufacturing pause from March 17 through April 27, 2020, period costs associated with the manufacturing expansion projects and increased mix of injector part sales which carry a lower margin.  

General and Administrative Expense

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

General and administrative expense

 

$

7,848

 

 

$

7,508

 

 

 

4.5

%

 

$

15,817

 

 

$

14,345

 

 

 

10.3

%

Percentage of sales

 

 

22.3

%

 

 

18.9

%

 

 

 

 

 

 

22.5

%

 

 

19.9

%

 

 

 

 

General and administrative expenses for the three months ended July 3, 2020 were $7.8 million, a 4.5% increase compared to the $7.5 million reported for the same period of 2019.  General and administrative expenses for the six months ended July 3, 2020 were $15.8 million, a 10.3% increase compared to the $14.3 million reported for the same period of 2019. The increase in general and administrative expenses for both periods was due to an increase in headcount and salary-related expenses, partially offset by a decrease in variable compensation and travel expenses, and for the six months also due to increased tax consulting and facilities costs.

Marketing and Selling Expense

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Marketing and selling expense

 

$

10,326

 

 

$

11,682

 

 

 

(11.6

)%

 

$

21,354

 

 

$

21,825

 

 

 

(2.2

)%

Percentage of sales

 

 

29.3

%

 

 

29.5

%

 

 

 

 

 

 

30.3

%

 

 

30.2

%

 

 

 

 

Marketing and selling expenses for the three months ended July 3, 2020 were $10.3 million, a 11.6% decrease compared to the $11.7 million reported for the same period of 2019.  The decrease in marketing and selling expenses was due to decreased trade show expenses and travel expenses, partially offset by increased advertising and promotional activities.

Marketing and selling expenses for the six months ended July 3, 2020 were $21.4 million, a 2.2% decrease compared to the $21.8 million reported for the same period of 2019.  The decrease in marketing and selling expenses was due to decreased trade show expenses and travel expenses, partially offset by increased advertising, promotional activities and salary-related expenses.

Research and Development Expense

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Research and development expense

 

$

7,311

 

 

$

6,098

 

 

 

19.9

%

 

$

14,209

 

 

$

11,733

 

 

 

21.1

%

Percentage of sales

 

 

20.8

%

 

 

15.4

%

 

 

 

 

 

 

20.2

%

 

 

16.3

%

 

 

 

 

Research and development expenses for the three months ended July 3, 2020 were $7.3 million, a 19.9% increase compared to the $6.1 million reported for the same period of 2019. Research and development expenses for the six months ended July 3, 2020 were $14.2 million, a 21.1% increase compared to the $11.7 million reported for the same period of 2019.  The increase in research and development expenses for both periods was primarily due to an increase in expenses related to clinical expenses associated with our EVO clinical trial in the U.S., and increased headcount and salary-related expenses, partially offset by variable compensation and travel expense.  

22


 

Other Income (Expense), Net

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Other income, net

 

$

439

 

 

$

434

 

 

 

1.2

%

 

$

282

 

 

$

725

 

 

 

(61.1

)%

Percentage of sales

 

 

1.2

%

 

 

1.1

%

 

 

 

 

 

 

0.4

%

 

 

1.0

%

 

 

 

 

 

 

*

Denotes change is greater than +100%.

Other income, net for the three months ended July 3, 2020 was $0.4 million, comparable to that reported for the same period of 2019.  Other income, net for the six months ended July 3, 2020 was $0.3 million compared to other income of $0.7 million reported for the same period of 2019.  The decrease in other income, net for the six months was due to decreases in interest income, as a result of lower interest rates, and royalty income, which was impacted by COVID-19 pandemic, partially offset by a decrease in foreign exchange losses (primarily the euro).  

Income Taxes

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Income tax provision (benefit)

 

$

556

 

 

$

1,131

 

 

 

(50.8

)%

 

$

(602

)

 

$

1,620

 

 

 

—*

 

 

 

*

Denotes change is greater than +100%.

We recorded income taxes of $0.6 million and $1.1 million for the three months ended July 3, 2020 and June 28, 2019, respectively, primarily due to pre-tax income generated in certain foreign jurisdictions.  Also for the three months ended June 28, 2019 withholding taxes on foreign operations.  We recorded an income tax benefit of $0.6 million for the six months ended July 3, 2020 due to the income tax benefit from the release of our U.S. valuation allowances, offset by income tax expense from profits generated by our foreign operations.  We recorded income taxes of $1.6 million for the six months ended June 28, 2019 primarily due to pre-tax income generated in certain foreign jurisdictions and withholding taxes on foreign operations.  In the fourth quarter of fiscal year 2019, we reversed all previously recorded withholding taxes recorded for 2019, at which time we formed STAAR Surgical UK Limited as a holding company for our foreign operations.  Based on the current tax treaties between the U.S., United Kingdom and Switzerland, we will no longer accrue for Switzerland withholding taxes on foreign earnings after fiscal 2018 (see also Note 10 in our fiscal 2019 Form 10-K for more information).  We have no unrecognized tax benefits pertaining to any uncertain tax positions as of any period presented.   

ASC 740 requires that a valuation allowance be established when it is more likely than not that all or a portion of a deferred tax asset may not be realizable.  As further described in Notes 1 and 10 of our fiscal 2019 Form 10-K, under the “incremental cash tax savings approach,” we recorded a valuation release of $3.0 million and $0.4 million against federal and certain states deferred tax assets, respectively.  During the six months ended July 3, 2020, we revised our global forecasts as a result of COVID-19, and released an additional $1.4 million of valuation allowance.  As of July 3, 2020, we released approximately $4.9 million of valuation allowance on our deferred tax assets in the U.S. jurisdiction utilizing the incremental cash tax savings approach.  The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. We considered the projected future income, tax planning strategies and all other available evidence both positive and negative, as well as results of recent operations in making this assessment.    In applying the incremental cash tax savings approach, we will continue to maintain a valuation allowance on the balance of the Company’s net U.S. deferred tax assets of $36.5 million.

Liquidity and Capital Resources

We believe that current cash, cash equivalents and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. We have experienced some delays in payments on accounts receivable as a result of the COVID-19 pandemic but expect this to improve during the third quarter of 2020 as our customers resume elective refractive surgery. This has had a temporary impact on our working capital.  However, at this time we are unaware of any impairment of assets resulting from the COVID19 pandemic.  The Company did not apply for or require financing available under the Coronavirus Aid, Relief, and Economic Security “CARES” Act and

23


 

does not expect to do so given the strength of our balance sheet.  Our financial condition at July 3, 2020 and January 3, 2020 included the following (in millions):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

 

2020 vs. 2019

 

Cash and cash equivalents

 

$

116.3

 

 

$

120.0

 

 

$

(3.7

)

Current assets

 

$

182.5

 

 

$

174.7

 

 

$

7.8

 

Current liabilities

 

 

31.6

 

 

 

34.5

 

 

 

(2.9

)

Working capital

 

$

150.9

 

 

$

140.2

 

 

$

10.7

 

 

We invest the net proceeds in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.  Additionally, at July 3, 2020, we have a line of credit with a Japanese lender, in the amount of $1.3 million, with $3.3 million of availability and a line of credit with a Swiss lender, in the amount of $1.1 million, which is fully available for borrowing.

Net cash used in operating activities was $8.2 million for the six months ended July 3, 2020 compared to net cash provided by operating activities of $4.2 million for the six months ended June 28, 2019.  Net cash used in operating activities for the six months ended July 3, 2020, consisted of $14.7 million in working-capital changes and a $1.3 million net loss, offset by $7.8 in non-cash items.  The change in net cash used in operating activities during the six months ended July 3, 2020 was due to a decrease in net working capital of $5.0 million, a decrease of $0.8 million in non-cash items and the net loss of $1.3 million during the six months ended July 3, 2020 compared to net income of $5.3 million during the six months ended June 28, 2019.

Net cash used in investing activities was $4.2 million and $4.6 million for the six months ended July 3, 2020 and June 28, 2019, respectively, and relate primarily to the acquisition of property, plant, and equipment.  

Net cash provided by financing activities was $8.7 million for the six months ended July 3, 2020 compared to net cash used in financing activities of $0.6 million for the six months ended June 28, 2019.  Net cash provided by financing activities for the six months ended July 3, 2020 consisted of $9.6 million of proceeds from the exercise of stock options, offset by $0.5 million repayment on the Japan line of credit and $0.3 million repayment of finance lease obligations.  

Credit Facilities and Commitments

Lines of Credit and Leases

See Notes 7 and 8 of the accompanying Condensed Consolidated Financial Statements.

Covenant Compliance

The Company is in compliance with the covenants of its credit facilities as of July 3, 2020.

Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015.  She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as that term is defined in the rules of the SEC, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

During the six months ended July 3, 2020, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended January 3, 2020.

24


 

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company.  Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective.  For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended July 3, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1.

From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business.  These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability.  STAAR maintains insurance coverage for various matters, including product liability and certain securities claims.  While we do not believe that any of the claims known is likely to have a material adverse effect on our financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm.

ITEM 1A.

RISK FACTORS

Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended January 3, 2020 and in “Part II—Item 1A—Risk Factors” of the Company’s Form 10-Q for the three months ended April 3, 2020. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.  

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable.

25


 

ITEM 5.

OTHER INFORMATION

Effective May 1, 2020, the Compensation Committee of the Board of Directors, as Administrator of STAAR’s Equity Incentive Plan, approved an amendment to Section 12.5 of STAAR’s Amended and Restated Omnibus Equity Incentive Plan to permit discretionary acceleration of vesting of equity awards granted to a non-employee director in the event of a Termination of Service, as defined by the Plan, after serving a minimum of at least one-half of the relevant term under any Award Agreement, as defined by the Plan.

ITEM 6.

EXHIBITS

 

   3.1

Amended and Restated Certificate of Incorporation.(1)

 

 

   3.2

Amended and Restated Bylaws.(2)

 

 

   4.1

Form of Certificate for Common Stock, par value $0.01 per share.(3)

 

 

 †4.2

Amended and Restated Omnibus Equity Incentive Plan.*

 

 

 †10.38

Letter of the Company dated June 30, 2020 to Patrick Williams, Chief Financial Officer, regarding compensation.*

 

 

 31.1

Certifications Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

 31.2

Certifications Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

 32.1

Certification Pursuant to 18 U.S.C. Section 1350, Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **

 

 

 101

Financial statements from the quarterly report on Form 10-Q of STAAR Surgical Company for the quarter ended July 3, 2020 formatted in Inline Extensible Business Reporting Language (iXBRL), are filed herewith and include: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Stockholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) the Notes to Condensed Consolidated Financial Statements tagged as blocks of text.*

 

 

 104

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended July 3, 2020, has been formatted in Inline XBRL with applicable taxonomy extension information contained in Exhibit 101.

 

(1)

Incorporated by reference to Appendix 2 of the Company’s Proxy Statement on Form DEF 14A as filed with the Commission on April 13, 2018

(2)

Incorporated by reference to Appendix 3 of the Company’s Proxy Statement on Form DEF 14A as filed with the Commission on April 13, 2018.

(3)

Incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company’s Registration Statement on Form 8‑A/A as filed with the Commission on April 18, 2003.

*

Filed herewith.

**

Furnished herewith.

Management contract or compensatory plan.

26


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

STAAR SURGICAL COMPANY

 

 

 

 

 

 

Dated:

 

August 5, 2020

By:

 

/s/ PATRICK F. WILLIAMS

 

 

 

 

 

Patrick F. Williams

 

 

 

 

 

Chief Financial Officer

 

 

 

 

 

(on behalf of the Registrant and as its principal financial officer)

 

27